Octant Bio is a technology company.
Octant Bio has raised $115.0M across 3 funding rounds.
Octant Bio has raised $115.0M in total across 3 funding rounds.
Octant Bio has raised $115.0M in total across 3 funding rounds.
Octant Bio's investors include Andreessen Horowitz, Angel investor, Catalio Capital, EQT Life Sciences, GSR Ventures, Illumina Ventures, Insight Partners, Kleiner Perkins, Kurma Partners, Polaris Partners, Polygon, Soffinova Partners.
Octant Bio is a therapeutics company developing small-molecule drugs that target cellular mechanisms driving diseases, particularly protein misfolding and mistrafficking, using synthetic biology, generative chemistry, and AI.[1][3][5] Its lead candidate, OCT-980, is an oral small molecule correcting rhodopsin gene mutations in RHO-adRP (a form of retinitis pigmentosa), aiming to restore retinal structure, improve low-light vision, and halt progression, with preclinical efficacy supporting clinical trials in early 2026.[2][3] Octant serves patients with genetically validated rare and complex diseases like retinal disorders, initially targeting underserved areas in ophthalmology, metabolism, immunology, and CNS, while solving limitations of traditional target-binding drug discovery by modulating function at scale.[1][2][5]
The company combines high-throughput generative biology (e.g., RNA-barcoded cell lines for deep mutational scanning), nano-scale chemistry for analog libraries, and ML-driven iteration via the Octant Navigator platform, enabling rapid design-build-test-learn cycles.[2][4] Growth momentum includes emerging from stealth in 2020 with a $30M Series A, building a pipeline for multi-mutant approaches to maximize patient coverage, and advancing OCT-980 toward clinic amid strong preclinical data.[2][3][7]
Octant Bio was founded in 2017 in Emeryville, California, by a team of technologists aiming to pioneer synthetic biology for drug discovery beyond single-target approaches.[1][5] Key founders include Sri Kosuri, who emphasized building hardware/software stacks to uncover multi-targeted drugs for complex diseases like diabetes, obesity, and cardiovascular issues, driven by the insight that traditional protein-binding methods fall short for multifactorial biology.[7] The idea emerged from advances in genetic engineering, allowing cells to compute biological data at scales surpassing simulations, mapping genetics-to-disease mechanisms.[5]
Early traction came via stealth development of multiplexed tech using synthetic biology, genome engineering, NGS, and computation; in 2020, they exited stealth with $30M Series A from investors like Ulu Ventures and Lux Capital, open-sourcing tech during COVID to accelerate progress, and shifting focus to genetically validated diseases society was neglecting.[6][7] Pivotal moments include iterative screening of 250,000+ molecules for OCT-980, yielding potent retinal correctors.[2]
Octant stands out in precision medicine through its Octant Navigator platform, integrating three pillars for mechanism-based screening:
Unlike purified protein-binding, Octant drugs cellular functions at scale, maximizing patient coverage from day one and enabling "first-in-disease" therapies like OCT-980 with strong preclinical safety/efficacy.[1][2][3] This antedisciplinary model—built by scientists, engineers, and operators—fosters rapid risk-taking for high-value diseases.[5]
Octant rides the precision medicine and generative biology wave, merging AI/ML, synthetic biology, and automation to decode disease complexity amid surging demand for multi-omics data and mechanism-focused drugs.[1][4][7] Timing aligns with post-2020 biotech maturation, where COVID accelerated open-source bio-tools and investor appetite for platform companies tackling "undruggable" pathways like protein trafficking in rare genetic diseases.[7]
Market forces favor it: aging populations drive retinal/metabolic needs (e.g., RHO-adRP affects thousands with no approved therapies), while AI-bio convergence (e.g., similar to Generate Biomedicines) lowers discovery costs and timelines.[1][2] Octant influences the ecosystem by advancing DMS for protein function mapping, inspiring multiplexed screening standards, and targeting immunology/CNS to broaden synthetic bio's therapeutic reach.[2][4][5]
Octant is poised to disrupt rare disease treatment with OCT-980's Phase 1 entry in early 2026, leveraging preclinical momentum to validate its platform and expand pipeline via Navigator to GPCRs, kinases, and multi-factorial areas like obesity.[2][3][4] Trends like AI-accelerated chemistry loops and regulatory nods for genetic correctors (e.g., in retina) will amplify growth, potentially drawing big pharma partnerships.
Its influence may evolve from stealth innovator to ecosystem leader, open-sourcing insights to standardize mechanism screening while scaling internal programs—ultimately delivering rational multi-target drugs that transform lives in complex diseases, fulfilling its mission to drug biology's full complexity.[5][7] This positions Octant as a high-momentum bet in next-gen therapeutics.
Octant Bio has raised $115.0M across 3 funding rounds. Most recently, it raised $80.0M Series B in April 2022.